Aligos Therapeutics (STU:5WK0) FCF Margin %: -819.69% (As of Mar. 2026)

What is Aligos Therapeutics FCF Margin %?

Aligos Therapeutics STU:5WK0 +6.75% 26 FCF Margin % is -819.69% as of Mar. 2026. GuruFocus rates STU:5WK0 with a GF Score™ of 26/100 and a GF Value™ of €2.40 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 948 Biotechnology companies, Aligos Therapeutics ranks worse than 83.76% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Aligos Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was €-20.07 Mil. Aligos Therapeutics's Revenue for the three months ended in Mar. 2026 was €2.45 Mil. Therefore, Aligos Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was -819.69%.

As of today, Aligos Therapeutics's current FCF Yield % is -235.31%.

The historical rank and industry rank for Aligos Therapeutics's FCF Margin % or its related term are showing as below:

STU:5WK0' s FCF Margin % Range Over the Past 10 Years
Min: -3794.14 Med: -2050.01 Max: -508.83
Current: -1801.92

During the past 8 years, the highest FCF Margin % of Aligos Therapeutics was -508.83%. The lowest was -3794.14%. And the median was -2050.01%.

STU:5WK0's FCF Margin % is ranked worse than
83.76% of 948 companies
in the Biotechnology industry
Industry Median: -83.535 vs STU:5WK0: -1801.92

Aligos Therapeutics FCF Margin % Related Terms

Aligos Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Aligos Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aligos Therapeutics FCF Margin % Chart

Aligos Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

FCF Margin %

Get a 7-Day Free Trial

-2,673.67

-577.64

-508.83

-2,050.28

-3,793.84

Aligos Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
FCF Margin %	Get a 7-Day Free Trial															-6,729.51	-1,617.32	-3,313.15	-12,950.69	-819.69

STU:5WK0 vs SNTI, NTRB, CRVO: FCF Margin % Comparison

For the Biotechnology subindustry, Aligos Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aligos Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Aligos Therapeutics's FCF Margin % falls into.

Save Embed

26GF Score

Aligos Therapeutics Inc STU:5WK0

FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Aligos Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Aligos Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-70.831	/	1.867
	=	-3,793.84 %

Aligos Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-20.066	/	2.448
	=	-819.69 %

Frequently Asked Questions Learn more about FCF Margin % →

What does a FCF Margin % of -819.69% mean?

Aligos Therapeutics (STU:5WK0) has a FCF Margin % of -819.69% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Aligos Therapeutics and its competitors. According to the industry distribution chart, Aligos Therapeutics ranks #794 out of 948 companies in the Biotechnology industry, placing it in the top 83.8%.

Is Aligos Therapeutics' FCF Margin % too high?

Aligos Therapeutics' current FCF Margin % is -819.69%. Based on the distribution chart, Aligos Therapeutics ranks #794 out of 948 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aligos Therapeutics has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Aligos Therapeutics' FCF Margin % compare to SNTI and NTRB?

According to the Biotechnology industry distribution chart, Aligos Therapeutics ranks #794 out of 948 companies for FCF Margin %. This places Aligos Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good FCF Margin % for a Biotechnology company?

A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high FCF Margin % mean?

A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Aligos Therapeutics and its competitors. Aligos Therapeutics's current FCF Margin % is -819.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Aligos Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Aligos Therapeutics (STU:5WK0) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.40, compared to a current price of €5.14 — trading 114.2% above its estimated fair value. The current FCF Margin % is -819.69%. Aligos Therapeutics' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is FCF Margin % calculated?

FCF Margin % is calculated from a company's financial statements. For Aligos Therapeutics (STU:5WK0), the current FCF Margin % is -819.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aligos Therapeutics (STU:5WK0) Overvalued in 2026?

Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be overvalued. The current stock price of €5.14 is trading 114.2% above its estimated GF Value™ of €2.40. GuruFocus considers Aligos Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:5WK0:

FCF Margin %: -819.69%
GF Value™: €2.40 vs. price of €5.14 (114.2% above fair value)
GF Score™: 26/100 with 4 warning signs

No single metric tells the full story. See the STU:5WK0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aligos Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies SNTI NTRB CRVO DARE INMB ATNM NNVC GRCE LSTA SGMO VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges ALGS:USA

Address One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080

Website https://www.aligos.com

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

26GF Score

Get the complete analysis for STU:5WK0

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.14

Price

€2.40

GF Value

View STU:5WK0 Analysis

See FCF Margin % data for all stocks →